Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 10.
doi: 10.1111/1471-0528.70075. Online ahead of print.

Obstetric and Neonatal Outcomes in Pregnancies From a Dedicated Cystic Fibrosis-Maternal Health Service: A Retrospective Study

Rebecca Scott  1   2 , Amy Downes  2   3 , Ladina Weitnauer  3 , Rebecca Dobra  4 , Natasha Singh  1 , Rachel Robinson  3 , Emily Diable  3 , Saraha Collins  3 , Elaine Bowman  3 , Thomas Tobin  3 , Andrew Jones  3   4 , Nicholas Simmonds  3   4 , Imogen Felton  3   4
Affiliations

Obstetric and Neonatal Outcomes in Pregnancies From a Dedicated Cystic Fibrosis-Maternal Health Service: A Retrospective Study

Rebecca Scott et al. BJOG. .

Abstract

Objective: A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF-Maternal Health service.

Design: Retrospective data review from a CF-Maternal Health service between September 2020 and February 2025.

Setting: A large adult-CF service in London, UK.

Population or sample: Pregnant fwCF attending the Royal Brompton Hospital CF Service.

Methods: Review of CF-Maternal Health service data.

Main outcome measures: Maternal, obstetric and neonatal outcomes.

Results: Fifty-three fwCF completed 67 pregnancies, with 69 infants born. There were no stillbirths, neonatal or maternal deaths. ETI-therapy was reported in 81% of pregnancies. In fwCF without CF-Diabetes, 57% developed gestational diabetes. Hospital admission to treat an infective pulmonary exacerbation was required in 31% of pregnancies. Forty-five percent of pregnancies delivered vaginally; 78% of babies were born at term. A major congenital abnormality was diagnosed in 4% of infants. Baseline lung-function correlated positively with birth-weight and gestation at birth.

Conclusions: FwCF have improved maternal, obstetric and neonatal outcomes since the introduction of ETI-therapy, within a dedicated CF-Maternal Health service.

Keywords: CFTR‐modulators; Elexacaftor/Tezacaftor/Ivacaftor; cystic fibrosis; maternal medicine; pregnancy.

PubMed Disclaimer

References

    1. Cystic Fibrosis Trust, “UK Cystic Fibrosis Registry 2022 Annual Data Report,” (2023).
    1. M. Shteinberg, J. Taylor‐Coussa, I. Durieu, and M. Cohen‐Cymberknoh, “Fertility and Pregnancy in Cystic Fibrosis,” Chest 160, no. 6 (2021): 2051–2060.
    1. E. Anthony, A. Oppenheimer, A. L. Case, J. R. Esterly, and R. M. Rothberg, “Cervical Mucus in Cystic Fibrosis: A Possible Cause of Infertility,” American Journal of Obstetrics and Gynecology 108, no. 4 (1970): 673.
    1. M. Shteinberg, L. A. Ben, D. G. Downey, et al., “Failure to Conceive in Women With CF Is Associated With Pancreatic Insufficiency and Advancing Age,” Journal of Cystic Fibrosis 18, no. 4 (2019): 525.
    1. A. Ashcroft, S. J. Chapman, and L. Mackillop, “The Outcome of Pregnancy in Women With Cystic Fibrosis: A UK Population‐Based Descriptive Study,” BJOG: An International Journal of Obstetrics & Gynaecology 127, no. 13 (2020): 1696–1703.

LinkOut - more resources